1. A patient with heterozygous familial hypercholesterolemia (HeFH) — a genetic disorder caused by loss-of-function mutations in the LDL receptor gene resulting in severely elevated LDL-C from birth — has been on maximally tolerated statin therapy for two years but has not achieved guideline-recommended LDL-C targets. Her physician adds evolocumab to her regimen. Which of the following best describes the primary mechanism by which evolocumab lowers LDL-C?
A) It inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and thereby upregulating LDL receptor expression on hepatocytes
B) It blocks the Niemann-Pick C1-like 1 (NPC1L1) transporter in intestinal enterocytes, reducing cholesterol absorption from the gut lumen
C) It binds and inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), a serine protease that normally targets LDL receptors for lysosomal degradation, thereby increasing receptor recycling to the hepatocyte surface and enhancing LDL clearance from plasma
D) It activates peroxisome proliferator-activated receptor alpha (PPARα) in hepatocytes and skeletal muscle, increasing fatty acid oxidation and reducing VLDL synthesis
E) It sequesters bile acids in the intestinal lumen by forming non-absorbable complexes, interrupting enterohepatic circulation and driving increased hepatic LDL receptor expression
ANSWER: C
Rationale:
Evolocumab is a fully human monoclonal antibody that targets PCSK9, a serine protease secreted by the liver that binds to LDL receptors on the hepatocyte surface and directs them toward lysosomal degradation rather than recycling back to the cell surface. By blocking this degradation pathway, evolocumab increases the number of functional LDL receptors available on hepatocytes, substantially enhancing the clearance of LDL particles from the circulation. In patients with HeFH, who have reduced LDL receptor function at baseline, this mechanism provides additive benefit on top of statin therapy by preserving whatever receptor activity remains. PCSK9 inhibitors consistently reduce LDL-C by approximately 50–60% on top of background statin therapy and have demonstrated cardiovascular outcome benefit in the FOURIER trial (evolocumab) and ODYSSEY OUTCOMES trial (alirocumab).
Option A: Option B: Option C: Option C is correct. Evolocumab inhibits PCSK9-mediated LDL receptor degradation, increasing receptor recycling to the hepatocyte surface and enhancing LDL clearance from plasma.
Option D: Option E:
Option A: Option A describes the mechanism of HMG-CoA reductase inhibitors (statins), not PCSK9 inhibitors. Statins reduce intracellular cholesterol synthesis, which secondarily upregulates LDL receptor expression, but this is a distinct mechanism from PCSK9 inhibition.
Option B: Option B describes the mechanism of ezetimibe, which inhibits the NPC1L1 transporter in intestinal brush-border cells to reduce dietary and biliary cholesterol absorption. This is unrelated to PCSK9.
Option D: Option D describes the mechanism of fibrates, which activate PPARα to reduce triglyceride synthesis and increase HDL. Fibrates do not primarily lower LDL-C through this pathway and are not PCSK9 inhibitors.
Option E: Option E describes the mechanism of bile acid sequestrants (e.g., cholestyramine, colesevelam), which trap bile acids in the gut to interrupt enterohepatic circulation and secondarily upregulate hepatic LDL receptors. This is not the mechanism of evolocumab.
2. A 58-year-old man is discharged from the hospital three days after an ST-elevation myocardial infarction (STEMI). His LDL-C on admission was 112 mg/dL. According to current ACC/AHA guideline-based lipid management for post-acute coronary syndrome (ACS) patients, which of the following best describes the appropriate pharmacological strategy and LDL-C target for this patient?
A) Initiate high-intensity statin therapy (e.g., atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) with a target LDL-C of less than 70 mg/dL; if this target is not achieved after maximally tolerated statin therapy, add ezetimibe and, if needed, a PCSK9 inhibitor
B) Initiate moderate-intensity statin therapy targeting a 30–49% reduction in LDL-C, with reassessment at 12 weeks and escalation only if the patient remains symptomatic
C) Begin fibrate therapy as first-line treatment because post-ACS patients frequently have mixed dyslipidemia with elevated triglycerides that requires PPARα activation before statin initiation
D) Defer pharmacological lipid-lowering therapy for 90 days post-ACS to allow spontaneous LDL-C normalization before establishing a baseline for treatment decisions
E) Initiate niacin as adjunctive therapy to the statin regimen because niacin raises HDL-C and reduces lipoprotein(a), providing additional cardiovascular protection in the post-ACS period
ANSWER: A
Rationale:
Post-ACS patients represent the highest-risk category in cardiovascular medicine, and guideline-directed therapy mandates high-intensity statin therapy initiated before or at hospital discharge. The ACC/AHA 2018 Cholesterol Guideline and subsequent 2019 focused update establish an LDL-C goal of less than 70 mg/dL for very high-risk patients (those with established ASCVD including recent ACS), with a further optional threshold of less than 55 mg/dL for patients experiencing a second major adverse cardiovascular event within two years. If high-intensity statin therapy alone does not achieve the LDL-C target, the stepwise addition of ezetimibe (which reduces LDL-C by an additional 15–20%) and then a PCSK9 inhibitor (which reduces LDL-C by an additional 50–60%) is supported by evidence from the IMPROVE-IT and FOURIER trials respectively. Early and aggressive LDL-C lowering post-ACS is associated with plaque stabilization and reduced risk of recurrent events.
Option A: Option A is correct. High-intensity statin therapy initiated at discharge with an LDL-C target of less than 70 mg/dL, with stepwise addition of ezetimibe and PCSK9 inhibitor if needed, reflects current ACC/AHA guideline recommendations for post-ACS management.
Option B: Option C: Option D: Option E:
Option B: Option B is incorrect. Moderate-intensity statin therapy is reserved for patients unable to tolerate high-intensity dosing or for primary prevention in lower-risk groups. Post-ACS patients require high-intensity therapy as the standard of care, not a moderate approach with delayed reassessment.
Option C: Option C is incorrect. Fibrates are not first-line agents in post-ACS lipid management. While hypertriglyceridemia may coexist, statins remain the cornerstone of post-ACS lipid therapy, and fibrates are added only when triglycerides are severely elevated (typically above 500 mg/dL) and pancreatitis risk is a concern.
Option D: Option D is incorrect. There is no rationale for deferring statin therapy 90 days post-ACS. Early initiation of high-intensity statin therapy — ideally before hospital discharge — is a quality performance measure and is associated with improved adherence and outcomes.
Option E: Option E is incorrect. Niacin was previously used as adjunctive therapy, but the AIM-HIGH and HPS2-THRIVE trials demonstrated no incremental cardiovascular benefit from adding niacin to statin therapy despite raising HDL-C, and niacin is no longer recommended as routine adjunctive treatment in post-ACS management.
3. A cardiologist is reviewing the lipid management strategy for a 67-year-old patient with ischemic cardiomyopathy and a left ventricular ejection fraction (LVEF) of 28%. The patient's LDL-C is 88 mg/dL. The cardiologist notes that despite robust evidence for statins in atherosclerotic cardiovascular disease, randomized controlled trials have not demonstrated mortality benefit from statin therapy initiated specifically for systolic heart failure. Which of the following best describes the leading proposed explanation for this "statin paradox" in heart failure?
A) Statins are rapidly metabolized by the failing myocardium, producing toxic metabolites that counteract their anti-inflammatory and plaque-stabilizing effects in patients with reduced ejection fraction
B) The neurohormonal activation characteristic of heart failure upregulates HMG-CoA reductase activity so completely that even high-intensity statin doses cannot achieve meaningful LDL-C reduction in this population
C) Statin therapy reduces coenzyme Q10 (ubiquinone) synthesis by inhibiting the mevalonate pathway, and this reduction in myocardial coenzyme Q10 directly worsens cardiac contractility in the failing heart
D) Patients with systolic heart failure have such severely impaired intestinal absorption due to gut edema that statins cannot achieve adequate bioavailability regardless of oral dose
E) In advanced heart failure, lower total cholesterol and LDL-C levels are associated with worse outcomes — a phenomenon called reverse epidemiology or the cholesterol paradox — suggesting that the expected benefit of LDL-C reduction may not apply in this population, and large randomized trials (CORONA and GISSI-HF) found no mortality benefit from rosuvastatin in patients with systolic heart failure
ANSWER: E
Rationale:
The statin paradox in heart failure refers to the observation that, unlike in atherosclerotic cardiovascular disease where lower LDL-C is clearly associated with better outcomes, patients with advanced systolic heart failure frequently exhibit an inverse relationship between cholesterol levels and survival — those with lower LDL-C tend to fare worse, not better. This reverse epidemiology is thought to reflect the catabolic state of heart failure, malnutrition, and the fact that lipoproteins may play a role in binding and neutralizing circulating endotoxins. The two landmark randomized trials testing statins specifically in systolic heart failure — CORONA (rosuvastatin 10 mg in ischemic systolic heart failure) and GISSI-HF (rosuvastatin 10 mg in mixed etiology heart failure) — both found no reduction in all-cause mortality or cardiovascular mortality despite achieving expected LDL-C reductions. Current guidelines do not recommend initiating statin therapy solely for heart failure management; however, patients who are already on statins for atherosclerotic indications are generally continued on therapy.
Option A: Option B: Option C: Option D: Option E: Option E is correct. Reverse epidemiology (the cholesterol paradox) and the negative findings of the CORONA and GISSI-HF trials form the primary evidence base for the statin paradox in systolic heart failure.
Option A: Option A is incorrect. There is no established mechanism by which the failing myocardium produces toxic statin metabolites. Statin metabolism is primarily hepatic via CYP3A4 or sulfation pathways and is not materially altered by reduced cardiac function.
Option B: Option B is incorrect. Heart failure does not cause complete upregulation of HMG-CoA reductase that would render statins ineffective. The CORONA and GISSI-HF trials documented expected LDL-C reductions, confirming statins remained pharmacologically active in heart failure patients.
Option C: Option C is incorrect as the primary explanation. While statin-related reductions in coenzyme Q10 synthesis via the mevalonate pathway are pharmacologically real, this mechanism has not been established as the leading explanation for the lack of mortality benefit in clinical heart failure trials, and coenzyme Q10 supplementation has not been shown to restore statin benefit in this population.
Option D: Option D is incorrect. Gut edema in heart failure can affect drug absorption for some agents, but statins are not reliably absorbed poorly in heart failure, and bioavailability impairment is not the accepted explanation for the negative trial results.
4. A 44-year-old woman presents to the emergency department with acute epigastric pain, nausea, and vomiting. Serum lipase is markedly elevated and her fasting triglyceride level is 1,840 mg/dL. She has no history of alcohol use and is not taking any medications known to elevate triglycerides. In addition to supportive care, which drug class is the most appropriate first-line pharmacological intervention to reduce triglyceride levels and reduce the risk of recurrent pancreatitis in this patient?
A) High-intensity statin therapy, because statins reduce VLDL synthesis and are the most evidence-supported agents for reducing cardiovascular risk across all lipid abnormalities including severe hypertriglyceridemia
B) Fibrates (e.g., fenofibrate or gemfibrozil), which activate PPARα (peroxisome proliferator-activated receptor alpha) to increase lipoprotein lipase expression, enhance triglyceride-rich lipoprotein clearance, and reduce hepatic VLDL synthesis, producing triglyceride reductions of 30–50%
C) Ezetimibe, because reducing intestinal cholesterol absorption secondarily lowers circulating triglyceride levels by reducing the flux of lipids entering the portal circulation after meals
D) Bile acid sequestrants, which interrupt enterohepatic bile acid circulation and drive increased hepatic conversion of cholesterol to bile acids, reducing circulating lipoproteins including triglyceride-rich VLDL
E) PCSK9 inhibitors, which by increasing hepatic LDL receptor expression secondarily enhance clearance of triglyceride-rich remnant lipoproteins as well as LDL particles
ANSWER: B
Rationale:
When fasting triglyceride levels exceed 500 mg/dL — and especially at levels above 1,000 mg/dL as seen here — the primary clinical concern shifts from cardiovascular risk reduction to prevention of acute pancreatitis. Fibrates are the drug class of first choice for severe hypertriglyceridemia because their mechanism is directly targeted at triglyceride metabolism. Fibrates activate PPARα, a nuclear transcription factor that upregulates lipoprotein lipase (LPL) and apolipoprotein C-II (a LPL activator) while downregulating apolipoprotein C-III (an LPL inhibitor), collectively accelerating the clearance of chylomicrons and VLDL from the circulation. Fibrates also reduce hepatic VLDL synthesis. The net result is a 30–50% reduction in triglycerides, which is far greater than what can be achieved with statins or ezetimibe. Omega-3 fatty acids (icosapentaenoic acid and docosahexaenoic acid) are a second-line option. Statins are not first-line for severe isolated hypertriglyceridemia, though they may be added later for concurrent LDL-C management.
Option A: Option B: Option B is correct. Fibrates activate PPARα to increase LPL activity and reduce VLDL synthesis, producing the largest triglyceride reductions of any oral drug class and representing first-line treatment for severe hypertriglyceridemia.
Option C: Option D: Option E:
Option A: Option A is incorrect. While statins modestly reduce triglycerides (approximately 10–20%), they are not first-line agents for severe hypertriglyceridemia presenting with pancreatitis risk. Their primary indication is LDL-C reduction and cardiovascular risk reduction.
Option C: Option C is incorrect. Ezetimibe inhibits NPC1L1-mediated cholesterol absorption and has minimal to no clinically meaningful effect on triglyceride levels. It is not indicated for hypertriglyceridemia management.
Option D: Option D is incorrect. Bile acid sequestrants lower LDL-C but can actually worsen hypertriglyceridemia by increasing hepatic VLDL synthesis as a compensatory response to bile acid depletion. They are contraindicated when triglycerides are significantly elevated.
Option E: Option E is incorrect. PCSK9 inhibitors primarily lower LDL-C by increasing hepatic LDL receptor expression. While they have modest effects on triglyceride-rich remnant lipoproteins, they are not first-line agents for severe hypertriglyceridemia and would not be the immediate intervention in a patient presenting with triglyceride-induced pancreatitis.
5. A 52-year-old man with type 2 diabetes mellitus and dyslipidemia is started on atorvastatin 40 mg daily for primary cardiovascular prevention. His other medications include metformin 1,000 mg twice daily and amlodipine 5 mg daily. Three months later he reports mild proximal muscle aching. His creatine kinase (CK) level is mildly elevated at 2.5 times the upper limit of normal. Which of the following pharmacokinetic properties of atorvastatin is most relevant to understanding its potential for drug interactions that could increase myopathy risk in this patient?
A) Atorvastatin undergoes extensive first-pass metabolism in the intestinal wall via glucuronidation by UGT1A3, making it susceptible to interactions with drugs that induce UGT enzymes, such as rifampin
B) Atorvastatin is a substrate for the organic anion transporting polypeptide 1B1 (OATP1B1) hepatic uptake transporter only, meaning its interaction risk is confined exclusively to drugs that inhibit this transporter
C) Atorvastatin is eliminated almost entirely by renal excretion, so any drug that reduces glomerular filtration rate will increase atorvastatin plasma concentrations and myopathy risk
D) Atorvastatin is metabolized primarily by CYP3A4 (cytochrome P450 3A4), and co-administration of CYP3A4 inhibitors — including certain calcium channel blockers such as amlodipine (a weak CYP3A4 inhibitor) and more potently azole antifungals, macrolide antibiotics, and HIV protease inhibitors — can increase atorvastatin plasma concentrations and myopathy risk
E) Atorvastatin is a prodrug that requires hepatic activation by CYP2C9 to its active hydroxyl acid form, and CYP2C9 poor metabolizers will fail to convert the drug and will derive no LDL-C-lowering benefit
ANSWER: D
Rationale:
Atorvastatin is metabolized primarily by CYP3A4, one of the most abundant cytochrome P450 enzymes in the liver and intestinal wall. This makes it susceptible to pharmacokinetic interactions with CYP3A4 inhibitors, which reduce atorvastatin clearance and raise plasma concentrations of the parent drug and its active metabolites — increasing the risk of dose-dependent adverse effects including myalgia, myopathy, and in severe cases rhabdomyolysis. Amlodipine is a weak CYP3A4 inhibitor; while its interaction with atorvastatin is generally modest, in combination with higher atorvastatin doses it may contribute to mildly elevated drug exposure. Strong CYP3A4 inhibitors such as itraconazole, clarithromycin, and ritonavir produce more clinically significant interactions and require either dose reduction or avoidance. In contrast, statins that are not CYP3A4 substrates — including pravastatin, rosuvastatin, and fluvastatin — have lower interaction potential via this pathway, which is clinically relevant when selecting a statin for a patient on multiple medications. The finding of mild CK elevation and myalgia in this patient warrants review of concurrent CYP3A4 inhibitors as a contributing factor.
Option A: Option B: Option C: Option D: Option D is correct. CYP3A4-mediated metabolism is the primary pharmacokinetic basis for atorvastatin's interaction profile, and co-administration with CYP3A4 inhibitors increases atorvastatin exposure and myopathy risk.
Option E:
Option A: Option A is incorrect. Atorvastatin does undergo some glucuronidation, but its primary metabolic pathway is CYP3A4, not UGT1A3 glucuronidation. UGT-based interactions are more relevant to certain other drugs and are not the primary interaction concern for atorvastatin.
Option B: Option B is incorrect. While atorvastatin is indeed an OATP1B1 substrate, stating that its interaction risk is confined exclusively to this transporter is incorrect. CYP3A4-mediated metabolism is an equally or more clinically important interaction pathway for atorvastatin.
Option C: Option C is incorrect. Atorvastatin is primarily eliminated by hepatic metabolism and biliary excretion, not by renal excretion. Unlike some other statins (e.g., pravastatin, which has significant renal elimination), atorvastatin does not require dose adjustment for renal impairment and its plasma concentrations are not meaningfully affected by reduced glomerular filtration rate.
Option E: Option E is incorrect. Atorvastatin is not a prodrug requiring CYP2C9 activation. It is active as administered (as its acid form). The statin that is most associated with CYP2C9 metabolism is fluvastatin, not atorvastatin.
6. A 28-year-old woman with homozygous familial hypercholesterolemia (HoFH) — in which both LDL receptor alleles are nonfunctional, producing LDL-C levels above 400 mg/dL from childhood — has failed maximal statin plus ezetimibe therapy and PCSK9 inhibitor therapy (which provided only minimal benefit due to absent LDL receptors). Her physician considers adding lomitapide. Which of the following correctly identifies the mechanism of action of lomitapide?
A) Lomitapide inhibits microsomal triglyceride transfer protein (MTP), an enzyme located in the endoplasmic reticulum of hepatocytes and enterocytes that is required for the assembly and secretion of VLDL and chylomicrons, thereby reducing the production and secretion of apolipoprotein B-containing lipoproteins regardless of LDL receptor status
B) Lomitapide is an antisense oligonucleotide that reduces hepatic synthesis of apolipoprotein B-100 by degrading its mRNA, lowering VLDL and LDL production through a post-transcriptional gene-silencing mechanism
C) Lomitapide activates LXR (liver X receptor), a nuclear receptor that upregulates reverse cholesterol transport by increasing ABCA1 and ABCG1 transporter expression on macrophages, reducing atherosclerotic plaque burden
D) Lomitapide binds covalently to PCSK9, permanently inactivating it and preventing LDL receptor degradation even in patients with absent or severely reduced LDL receptor expression
E) Lomitapide inhibits cholesterol ester transfer protein (CETP), which normally transfers cholesterol esters from HDL to VLDL and LDL, thereby raising HDL-C and reducing LDL-C in patients with functional LDL receptors
ANSWER: A
Rationale:
Lomitapide is a small-molecule inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme located in the endoplasmic reticulum lumen of hepatocytes and enterocytes that is essential for the assembly of lipid-protein complexes. MTP transfers triglycerides, phospholipids, and cholesterol esters onto nascent apolipoprotein B (apoB) polypeptides, a process required for the formation and secretion of VLDL in the liver and chylomicrons in the intestine. By blocking MTP, lomitapide prevents the lipidation of apoB, causing apoB-containing lipoproteins (VLDL, LDL, and chylomicrons) to fail to form and be secreted — reducing plasma LDL-C independently of LDL receptor status. This mechanism is particularly valuable in HoFH patients, who have little or no functional LDL receptor activity and therefore do not respond meaningfully to PCSK9 inhibitors (which work by increasing LDL receptor recycling). Lomitapide is FDA-approved as an adjunct to a low-fat diet and other lipid-lowering therapies for adults with HoFH. Its major side effects include hepatotoxicity (with a REMS program) and gastrointestinal adverse effects from fat malabsorption.
Option A: Option A is correct. Lomitapide inhibits MTP in the endoplasmic reticulum, blocking assembly and secretion of apoB-containing lipoproteins — an LDL receptor-independent mechanism critical for HoFH management.
Option B: Option C: Option D: Option E:
Option B: Option B describes the mechanism of mipomersen, an antisense oligonucleotide (ASO) that targets apoB-100 mRNA to reduce VLDL and LDL production. Mipomersen is a different drug with a different mechanism; both are approved for HoFH but should not be confused.
Option C: Option C describes LXR agonism, which is a research target for reverse cholesterol transport but is not the mechanism of lomitapide and represents no currently approved drug in this class.
Option D: Option D is incorrect. Lomitapide does not interact with PCSK9 and does not function through covalent inactivation of any target. Covalent PCSK9 binding is not the mechanism of any currently approved lipid-lowering drug.
Option E: Option E describes the mechanism of CETP inhibitors (e.g., anacetrapib, evacetrapib), which raise HDL-C by reducing cholesterol ester transfer from HDL to apoB-containing lipoproteins. This is an entirely distinct mechanism from MTP inhibition and is not the mechanism of lomitapide.
7. A 61-year-old man with established atherosclerotic cardiovascular disease (ASCVD) is on atorvastatin 80 mg daily but his LDL-C remains at 82 mg/dL, above his target of less than 70 mg/dL. His physician adds ezetimibe 10 mg daily. Which of the following correctly identifies the molecular target and site of action of ezetimibe?
A) Ezetimibe inhibits HMG-CoA reductase in hepatocytes, providing additive cholesterol synthesis inhibition when combined with statin therapy and producing a synergistic LDL-C reduction through dual blockade of the same enzymatic pathway
B) Ezetimibe activates the farnesoid X receptor (FXR) in intestinal enterocytes, increasing bile acid synthesis and reducing the enterohepatic recirculation of cholesterol-rich bile acids back to the liver
C) Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) sterol transporter located on the apical brush border of small intestinal enterocytes, blocking the absorption of both dietary cholesterol and biliary cholesterol from the intestinal lumen
D) Ezetimibe binds to the bile acid receptor TGR5 on intestinal L-cells, reducing GLP-1 secretion and thereby decreasing postprandial chylomicron assembly and cholesterol absorption
E) Ezetimibe inhibits pancreatic cholesterol esterase (also called bile salt-stimulated lipase), preventing the hydrolysis of cholesterol esters in the intestinal lumen and reducing the pool of free cholesterol available for absorption
ANSWER: C
Rationale:
Ezetimibe selectively inhibits NPC1L1 (Niemann-Pick C1-like 1), a sterol transporter expressed on the apical membrane of enterocytes in the proximal small intestine. NPC1L1 is the primary transporter responsible for the uptake of free cholesterol from the intestinal lumen into enterocytes — this includes both dietary cholesterol and biliary cholesterol (which constitutes the larger fraction of intestinal cholesterol in most individuals). By blocking NPC1L1, ezetimibe reduces the amount of cholesterol delivered to the liver via chylomicrons, which lowers hepatic cholesterol content and secondarily upregulates hepatic LDL receptor expression, increasing LDL clearance from the circulation. Because ezetimibe acts at a different step in cholesterol homeostasis than statins (intestinal absorption vs. hepatic synthesis), the combination is complementary and produces additive LDL-C reduction. The IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin in post-ACS patients reduced the composite cardiovascular endpoint, confirming that this additional LDL-C lowering translates into clinical benefit. Ezetimibe also undergoes glucuronide conjugation in the intestinal wall and enterohepatic recirculation, which prolongs its duration of action.
Option A: Option B: Option C: Option C is correct. Ezetimibe inhibits NPC1L1 on the intestinal brush border, reducing absorption of both dietary and biliary cholesterol and secondarily increasing hepatic LDL receptor expression.
Option D: Option E:
Option A: Option A is incorrect. Ezetimibe does not inhibit HMG-CoA reductase and has no direct effect on hepatic cholesterol synthesis. Its mechanism is entirely distinct from that of statins and acts at the intestinal absorption level.
Option B: Option B is incorrect. Ezetimibe does not activate FXR or alter bile acid synthesis. FXR agonism is the mechanism of obeticholic acid, a bile acid analogue used in primary biliary cholangitis, not a lipid-lowering drug in current cardiovascular practice.
Option D: Option D is incorrect. Ezetimibe does not act on TGR5, does not influence GLP-1 secretion, and does not affect chylomicron assembly through hormonal signaling. TGR5 is a bile acid receptor involved in metabolic regulation, not the target of ezetimibe.
Option E: Option E is incorrect. Ezetimibe does not inhibit pancreatic cholesterol esterase. Inhibition of pancreatic lipases and esterases is the mechanism of orlistat (a weight-loss drug that inhibits pancreatic lipase to reduce fat absorption), which is pharmacologically unrelated to ezetimibe.
8. A 59-year-old man with type 2 diabetes and established ASCVD is on maximally tolerated statin therapy with well-controlled LDL-C at 58 mg/dL, but his fasting triglycerides remain persistently elevated at 210 mg/dL. His physician considers adding icosapentaenoic acid (IPE; brand name Vascepa) 4 g daily. Which of the following best describes the evidence base and distinguishing pharmacological feature of high-dose icosapentaenoic acid compared to mixed omega-3 formulations containing both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)?
A) Icosapentaenoic acid was studied in the ODYSSEY OUTCOMES trial and demonstrated a significant reduction in major adverse cardiovascular events compared to placebo in patients with recent ACS and elevated triglycerides, while mixed EPA/DHA formulations were not studied in cardiovascular outcome trials
B) The REDUCE-IT trial demonstrated that icosapentaenoic acid 4 g daily significantly reduced major adverse cardiovascular events (MACE) by approximately 25% relative risk reduction compared to mineral oil placebo in patients with elevated triglycerides on statin therapy, while mixed EPA/DHA formulations (studied in STRENGTH and ORIGIN) did not demonstrate significant cardiovascular event reduction
C) Icosapentaenoic acid lowers triglycerides exclusively by activating PPARα in hepatocytes, a mechanism shared by fibrates but not by mixed omega-3 formulations, which reduce triglycerides by a completely unrelated receptor-independent pathway
D) Icosapentaenoic acid raises LDL-C significantly in most patients with hypertriglyceridemia, and the REDUCE-IT trial showed that this LDL-C increase was offset by a parallel reduction in Lp(a) lipoprotein, explaining the net cardiovascular benefit observed
E) Icosapentaenoic acid is a prodrug that requires hepatic desaturation to its active docosapentaenoic acid metabolite, while mixed EPA/DHA formulations are already in their active form and therefore produce faster but less sustained triglyceride lowering
ANSWER: B
Rationale:
Icosapentaenoic acid (IPE), a purified form of EPA given as the ethyl ester at 4 g daily, was studied in the REDUCE-IT trial (Reduction of Cardiovascular Events with Icosapentaenoic Acid-Intervention Trial), which enrolled patients with elevated triglycerides (135–499 mg/dL) who were on stable statin therapy. The trial demonstrated an approximately 25% relative risk reduction in MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization) compared to mineral oil placebo, leading to FDA approval of Vascepa for cardiovascular risk reduction in this population. In contrast, the STRENGTH trial (omega-3 carboxylic acids containing both EPA and DHA) and the ORIGIN trial (omega-3 fatty acids in dysglycemia) did not demonstrate significant cardiovascular event reduction, raising the hypothesis that EPA alone — or the specific formulation — may be responsible for the benefit seen in REDUCE-IT. The mechanisms by which EPA reduces cardiovascular events beyond triglyceride lowering remain under investigation and may include anti-inflammatory, anti-thrombotic, and membrane-stabilizing effects.
Option A: Option B: Option B is correct. REDUCE-IT demonstrated significant MACE reduction with IPE 4 g daily in patients with elevated triglycerides on statin therapy, while mixed EPA/DHA formulations studied in STRENGTH and ORIGIN did not demonstrate equivalent benefit.
Option C: Option D: Option E:
Option A: Option A is incorrect. ODYSSEY OUTCOMES was the cardiovascular outcomes trial for alirocumab (a PCSK9 inhibitor), not for icosapentaenoic acid. Icosapentaenoic acid was studied in REDUCE-IT.
Option C: Option C is incorrect. Icosapentaenoic acid does not reduce triglycerides exclusively via PPARα activation. Omega-3 fatty acids reduce VLDL synthesis and may enhance triglyceride clearance through multiple mechanisms, and the mechanism of EPA is not identical to fibrate-mediated PPARα agonism.
Option D: Option D is incorrect. Icosapentaenoic acid does not significantly raise LDL-C. In contrast, mixed EPA/DHA formulations (particularly those with high DHA content) can modestly raise LDL-C in some patients with hypertriglyceridemia, which was one proposed concern about mixed formulations.
Option E: Option E is incorrect. Icosapentaenoic acid is not a prodrug requiring conversion to docosapentaenoic acid. It is active as administered and undergoes beta-oxidation and incorporation into membrane phospholipids rather than a prodrug activation step.
9. An 81-year-old woman with hypertension and osteoarthritis but no prior history of myocardial infarction, stroke, or other atherosclerotic cardiovascular disease is currently taking atorvastatin 20 mg daily, which was started five years ago for primary prevention based on a calculated 10-year ASCVD risk above 10%. She has no diabetes. Her daughter asks the physician whether her mother should continue the statin given her advanced age and the pill burden. Which of the following statements best reflects current evidence and guideline considerations regarding statin therapy for primary cardiovascular prevention in adults over 75 years of age?
A) Statin therapy for primary prevention in adults over 75 is strongly contraindicated because the excess risk of statin-induced rhabdomyolysis in this age group completely offsets any cardiovascular benefit, and current ACC/AHA guidelines recommend discontinuing statins in all patients above age 75
B) The benefit of statin therapy for primary prevention is identical in adults over 75 compared to younger adults, and no age-specific considerations are needed — the same 10-year ASCVD risk threshold of 7.5% applies uniformly across all age groups without modification
C) Adults over 75 have uniformly favorable benefit-risk profiles for statin primary prevention because long-term atherosclerosis burden guarantees high absolute cardiovascular event rates, meaning absolute risk reduction will always exceed drug toxicity risk regardless of frailty or comorbidity
D) Statins should be discontinued in all patients over 75 regardless of indication because pharmacokinetic changes in elderly patients reliably increase statin plasma concentrations to toxic levels, creating unavoidable myopathy and hepatotoxicity in this age group
E) Evidence for statin primary prevention in adults over 75 is more limited than in younger adults, and current guidelines recommend a clinician-patient discussion weighing individual cardiovascular risk, life expectancy, frailty, polypharmacy burden, and patient preferences; deprescribing may be appropriate for frail elderly patients with limited life expectancy, while those with high cardiovascular risk and good functional status may still benefit
ANSWER: E
Rationale:
The evidence base for statin therapy in primary cardiovascular prevention is most robust for adults aged 40–75 with elevated 10-year ASCVD risk. In adults over 75, the data are more limited — most major statin primary prevention trials enrolled relatively few patients in this age group, and the balance of benefit versus risk is less clearly defined. The ACC/AHA 2018 Cholesterol Guideline explicitly identifies adults over 75 as a population in which the decision to initiate or continue statin therapy for primary prevention should involve a risk discussion that accounts for potential benefits (cardiovascular event reduction), potential harms (myopathy risk, drug interactions in polypharmacy, falls risk), overall health status, frailty, life expectancy, and patient values and preferences. Deprescribing — the intentional discontinuation of a medication whose risks outweigh benefits in a specific patient context — is a recognized and evidence-supported strategy for frail elderly patients on statins for primary prevention who have limited life expectancy or who experience statin-related side effects. Patients already established on statins for secondary prevention (established ASCVD) represent a different clinical situation and are generally continued unless tolerability becomes a significant issue.
Option A: Option B: Option C: Option D: Option E: Option E is correct. A shared decision-making approach that weighs individual cardiovascular risk, life expectancy, frailty, polypharmacy, and patient preferences is the recommended framework for statin primary prevention decisions in adults over 75.
Option A: Option A is incorrect. Rhabdomyolysis is a rare but serious statin complication; it does not completely offset cardiovascular benefit in all elderly patients, and ACC/AHA guidelines do not recommend blanket discontinuation of statins in all patients above age 75. Statin decisions in the elderly are individualized, not categorically prohibited.
Option B: Option B is incorrect. Age-specific considerations are explicitly recommended by guidelines for adults over 75 in primary prevention. The 10-year risk calculator may underestimate or overestimate risk in older adults, and additional factors including frailty, comorbidity, and life expectancy must be incorporated into the decision.
Option C: Option C is incorrect. High atherosclerosis burden does not guarantee that absolute risk reduction will always exceed drug toxicity risk in every elderly patient. Frailty, limited life expectancy, polypharmacy, and low remaining time horizon can all reduce the net benefit of primary prevention statin therapy.
Option D: Option D is incorrect. Age-related pharmacokinetic changes can modestly increase statin exposure in some elderly patients, but this does not reliably produce toxic concentrations in all patients above 75. Dose adjustment and careful monitoring are appropriate but blanket contraindication is not supported.
10. A 64-year-old man with stage 4 chronic kidney disease (CKD) — defined as a GFR (glomerular filtration rate) between 15 and 29 mL/min/1.73m² — requires statin therapy for secondary cardiovascular prevention following a recent coronary artery bypass graft. His nephrologist asks the cardiologist which statin is most appropriate given his significantly reduced renal function. Which of the following correctly identifies the statin(s) most suitable for patients with advanced CKD, and explains why?
A) Atorvastatin and simvastatin are the preferred statins in advanced CKD because they are exclusively metabolized by CYP3A4 in the liver with no renal component whatsoever, meaning renal impairment has absolutely no effect on their pharmacokinetics or safety profile
B) Lovastatin is the preferred statin in advanced CKD because it is a prodrug activated in the kidney, and reduced renal activation in CKD results in lower active drug levels and therefore reduced myopathy risk compared to hepatically-activated statins
C) All statins require dose reduction by 50% in patients with GFR below 30 mL/min because all statins undergo significant renal tubular secretion as their primary elimination pathway, making them uniformly affected by reduced GFR to the same degree
D) Pravastatin and fluvastatin are among the statins considered safer in advanced CKD because they undergo predominantly hepatic metabolism with significant fecal/biliary elimination and less reliance on renal excretion; rosuvastatin, while predominantly hepatically eliminated, requires dose adjustment (maximum 10 mg daily) in severe renal impairment; in contrast, simvastatin and lovastatin carry higher myopathy risk in CKD due to accumulation
E) Rosuvastatin is absolutely contraindicated in all stages of CKD because it is the only statin with significant renal tubular secretion as its primary elimination pathway, making it uniquely dangerous across the entire spectrum of kidney disease from stage 1 through end-stage renal disease
ANSWER: D
Rationale:
Statin selection in patients with advanced CKD requires attention to each drug's elimination pathway and the degree to which renal impairment affects drug accumulation. Pravastatin undergoes partial renal elimination (approximately 20% as unchanged drug in urine) but also significant hepatic metabolism and biliary excretion; it is generally considered safe in CKD without dose adjustment up to moderate impairment, though modest dose reduction is sometimes recommended in severe CKD. Fluvastatin is extensively metabolized by CYP2C9 with primarily fecal elimination and minimal renal excretion, making it relatively safe in CKD. Rosuvastatin is primarily eliminated via fecal/biliary routes with approximately 10% renal excretion; it does not require dose adjustment in mild to moderate CKD but the FDA label recommends a maximum dose of 10 mg daily in patients with severe renal impairment (GFR below 30 mL/min) not on dialysis. Simvastatin and lovastatin are CYP3A4-metabolized statins whose active metabolites (the open-acid forms) are more susceptible to accumulation in CKD due to reduced clearance of active metabolites, increasing myopathy and rhabdomyolysis risk. Atorvastatin is primarily hepatically eliminated and is often used in CKD, including dialysis patients, without dose adjustment, but accumulation of active metabolites can occur in severe CKD. The SHARP trial specifically studied simvastatin plus ezetimibe in CKD patients and demonstrated cardiovascular benefit, helping establish the evidence base for lipid-lowering in this population.
Option A: Option B: Option C: Option D: Option D is correct. Pravastatin and fluvastatin have relatively low renal dependence; rosuvastatin requires dose capping in severe CKD; simvastatin and lovastatin carry higher accumulation and myopathy risk in CKD.
Option E:
Option A: Option A overstates the case for atorvastatin and simvastatin. While atorvastatin is predominantly hepatically eliminated, active metabolites can accumulate in severe CKD. Simvastatin carries a higher myopathy risk in CKD patients, particularly at higher doses, and is not considered uniformly safe in advanced CKD.
Option B: Option B is incorrect. Lovastatin is a prodrug that is activated by hepatic hydrolysis to its active hydroxy acid form, not by renal activation. Renal impairment does not reduce lovastatin activation; instead, it reduces clearance of active metabolites, increasing accumulation and myopathy risk.
Option C: Option C is incorrect. Statins differ substantially in their reliance on renal excretion. Not all statins undergo significant renal tubular secretion, and a blanket 50% dose reduction rule is not supported by prescribing information or clinical guidelines.
Option E: Option E is incorrect. Rosuvastatin is not absolutely contraindicated in all CKD stages. It is used in CKD — including in dialysis patients — with appropriate dose adjustment (maximum 10 mg daily in severe renal impairment). Characterizing it as uniquely dangerous across all CKD stages is not supported by evidence or labeling.
11. A 55-year-old man with heterozygous familial hypercholesterolemia and documented ASCVD has not achieved his LDL-C goal on maximally tolerated statin plus ezetimibe therapy. His cardiologist considers inclisiran, a recently FDA-approved agent. Which of the following correctly describes the mechanism of action of inclisiran and how it differs from the PCSK9 monoclonal antibodies evolocumab and alirocumab?
A) Inclisiran is a small interfering RNA (siRNA) — a short double-stranded RNA molecule — that is delivered to hepatocytes via conjugation to N-acetylgalactosamine (GalNAc), where it is incorporated into the RNA-induced silencing complex (RISC) and catalytically degrades PCSK9 mRNA, preventing PCSK9 protein synthesis rather than neutralizing the secreted protein; this mechanism allows twice-yearly subcutaneous dosing after the initial loading doses
B) Inclisiran is a monoclonal antibody that targets PCSK9 with higher binding affinity than evolocumab or alirocumab, allowing less frequent dosing (twice yearly vs. every two to four weeks) while using the same extracellular protein-neutralization mechanism
C) Inclisiran is an antisense oligonucleotide (ASO) — a single-stranded DNA analog — that binds to PCSK9 mRNA in the cytoplasm and recruits RNase H to degrade the target mRNA, reducing PCSK9 protein production; it differs from siRNA in that it does not require loading into a multiprotein silencing complex
D) Inclisiran inhibits the intracellular cleavage of the PCSK9 precursor protein by furin protease in the trans-Golgi network, preventing the maturation and secretion of active PCSK9 into the circulation without affecting PCSK9 gene transcription or mRNA levels
E) Inclisiran is a gene therapy vector that delivers a functional LDL receptor gene to hepatocytes using an adeno-associated virus (AAV) carrier, permanently correcting the underlying receptor deficiency in familial hypercholesterolemia patients and eliminating the need for ongoing pharmacotherapy
ANSWER: A
Rationale:
Inclisiran is a first-in-class small interfering RNA (siRNA) therapeutic targeting PCSK9. Its mechanism involves sequence-specific degradation of PCSK9 mRNA rather than neutralization of the secreted PCSK9 protein. The siRNA molecule is conjugated to triantennary N-acetylgalactosamine (GalNAc), which binds with high affinity to asialoglycoprotein receptors on the surface of hepatocytes, enabling targeted delivery to the liver. Once inside the hepatocyte, the siRNA is incorporated into the RNA-induced silencing complex (RISC), where the antisense strand guides RISC to the complementary PCSK9 mRNA sequence. The RISC complex then catalytically cleaves the mRNA, preventing translation into PCSK9 protein. Because the RISC complex is catalytic and can cleave multiple mRNA copies, the effect is durable — inclisiran requires only twice-yearly subcutaneous dosing after an initial dose and a second dose at three months. This contrasts with PCSK9 monoclonal antibodies (evolocumab and alirocumab), which neutralize already-secreted extracellular PCSK9 protein and require dosing every two to four weeks due to normal antibody clearance. Both inclisiran and the PCSK9 antibodies ultimately increase LDL receptor recycling and LDL-C clearance by the same downstream pathway, but through mechanistically distinct upstream interventions. Inclisiran reduces LDL-C by approximately 50% on background statin therapy, comparable to the PCSK9 antibodies.
Option A: Option A is correct. Inclisiran is a GalNAc-conjugated siRNA that degrades PCSK9 mRNA via RISC-mediated catalytic cleavage, allowing twice-yearly dosing — a mechanistically distinct approach from the PCSK9 monoclonal antibodies.
Option B: Option C: Option D: Option E:
Option B: Option B is incorrect. Inclisiran is not a monoclonal antibody and does not use a protein-neutralization mechanism. Describing it as a higher-affinity antibody with the same mechanism is incorrect — the mechanism is fundamentally different (RNA interference vs. protein binding).
Option C: Option C describes the mechanism of antisense oligonucleotides (ASOs) such as mipomersen, not inclisiran. While both ASOs and siRNAs reduce target protein production at the mRNA level, they differ in their mechanism (RNase H recruitment vs. RISC loading), structure (single-stranded vs. double-stranded), and pharmacological behavior.
Option D: Option D is incorrect. Inclisiran does not inhibit furin-mediated cleavage of the PCSK9 precursor in the Golgi. Furin inhibition has been explored as a research concept but is not the mechanism of inclisiran.
Option E: Option E is incorrect. Inclisiran is not a gene therapy and does not deliver an LDL receptor gene. It is an RNA interference agent that reduces endogenous PCSK9 expression; it does not alter the genome or deliver replacement genes.
12. A 50-year-old man with mixed dyslipidemia characterized by moderately elevated triglycerides (380 mg/dL), low HDL-C (32 mg/dL), and mildly elevated LDL-C is started on fenofibrate in addition to statin therapy. Which of the following correctly identifies the primary molecular mechanism by which fenofibrate and other fibrates reduce triglycerides and raise HDL-C?
A) Fibrates inhibit diacylglycerol acyltransferase (DGAT) in hepatocytes, the final enzyme in triglyceride biosynthesis, directly reducing the assembly of triglyceride-rich VLDL particles without affecting gene transcription
B) Fibrates activate the nuclear bile acid receptor FXR (farnesoid X receptor), increasing bile acid synthesis from cholesterol and secondarily reducing VLDL cholesterol content by depleting the hepatic cholesterol pool available for lipoprotein assembly
C) Fibrates activate PPARα (peroxisome proliferator-activated receptor alpha), a nuclear transcription factor that upregulates lipoprotein lipase (LPL) and apolipoprotein A-I (apoA-I) expression while downregulating apolipoprotein C-III (apoC-III), an endogenous LPL inhibitor — collectively increasing triglyceride-rich lipoprotein clearance, reducing VLDL synthesis, and raising HDL-C
D) Fibrates inhibit cholesterol ester transfer protein (CETP), reducing the transfer of cholesterol esters from HDL to VLDL and thereby simultaneously raising HDL-C and lowering circulating triglyceride-rich particles
E) Fibrates competitively inhibit the active site of HMG-CoA reductase with lower affinity than statins, producing modest reductions in cholesterol synthesis that indirectly lower VLDL production and raise HDL through a shared mevalonate pathway mechanism
ANSWER: C
Rationale:
Fibrates are agonists of PPARα (peroxisome proliferator-activated receptor alpha), a ligand-activated nuclear transcription factor expressed predominantly in the liver, skeletal muscle, and heart. When activated by fibrates, PPARα translocates to the nucleus and heterodimerizes with the retinoid X receptor (RXR), binding to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes. Key transcriptional effects include: upregulation of lipoprotein lipase (LPL), the enzyme responsible for hydrolyzing triglycerides in chylomicrons and VLDL; upregulation of apolipoprotein A-I (apoA-I) and apoA-II, the major structural proteins of HDL, increasing HDL particle formation; and downregulation of apolipoprotein C-III (apoC-III), an endogenous inhibitor of LPL that, when reduced, further accelerates triglyceride-rich lipoprotein clearance. PPARα activation also increases hepatic fatty acid beta-oxidation, reducing the substrate available for VLDL triglyceride synthesis. The net pharmacological result is a 30–50% reduction in triglycerides, a 10–20% increase in HDL-C, and a modest or variable effect on LDL-C. Fibrates are the drug class of first choice for isolated severe hypertriglyceridemia (especially above 500 mg/dL) and are useful in mixed dyslipidemia as add-on therapy.
Option A: Option B: Option C: Option C is correct. Fibrates activate PPARα, upregulating LPL and apoA-I while downregulating apoC-III, producing their characteristic triglyceride reduction and HDL-C elevation through coordinated transcriptional regulation.
Option D: Option E:
Option A: Option A is incorrect. Fibrates do not inhibit DGAT directly. They act upstream through nuclear receptor-mediated transcriptional regulation of multiple lipid metabolism genes, not through direct enzymatic inhibition of a single triglyceride synthesis step.
Option B: Option B is incorrect. Fibrates do not activate FXR. FXR is the primary bile acid nuclear receptor activated by bile acids and obeticholic acid. The PPARα-mediated mechanism of fibrates is distinct from bile acid receptor signaling.
Option D: Option D describes the mechanism of CETP inhibitors (e.g., anacetrapib, dalcetrapib), which reduce cholesterol ester transfer from HDL to apoB-containing lipoproteins. This is not the mechanism of fibrates.
Option E: Option E is incorrect. Fibrates do not inhibit HMG-CoA reductase. Their mechanism is entirely distinct from statins, operating through nuclear receptor activation rather than enzyme inhibition of the cholesterol synthesis pathway.
13. A cardiologist is explaining to a cardiology fellow why ezetimibe is added to statin therapy in post-ACS patients who have not achieved an LDL-C below 70 mg/dL on maximally tolerated statin alone. The fellow asks what clinical trial evidence supports this practice and whether it demonstrates hard cardiovascular endpoint benefit beyond LDL-C reduction alone. Which of the following correctly identifies the trial and its primary finding?
A) The SHARP trial randomly assigned patients with chronic kidney disease to simvastatin plus ezetimibe versus placebo and demonstrated a significant reduction in major atherosclerotic events, establishing the role of this combination in CKD — but did not include a post-ACS population or provide evidence for ezetimibe added to statin in that specific setting
B) The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) randomly assigned over 18,000 post-ACS patients to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo and demonstrated a statistically significant reduction in the primary composite cardiovascular endpoint, confirming that additional LDL-C lowering beyond statin monotherapy with ezetimibe produces incremental cardiovascular benefit
C) The FOURIER trial randomly assigned patients with established ASCVD and elevated LDL-C on statin therapy to evolocumab versus placebo and demonstrated significant MACE reduction — and because ezetimibe and PCSK9 inhibitors share the same downstream mechanism of increasing LDL receptor expression, this trial is cited as the primary evidence for ezetimibe added to statins post-ACS
D) The ACCORD Lipid trial demonstrated that adding fenofibrate to simvastatin in patients with type 2 diabetes did not reduce cardiovascular events, which by extension established that non-statin lipid-lowering agents including ezetimibe provide no incremental benefit post-ACS
E) The JUPITER trial demonstrated that rosuvastatin reduced cardiovascular events in primary prevention patients with elevated hsCRP, and this result was extrapolated to support ezetimibe use post-ACS on the basis that both agents reduce LDL-C through receptor-independent mechanisms
ANSWER: B
Rationale:
The IMPROVE-IT trial was the pivotal study that established the cardiovascular benefit of adding ezetimibe to statin therapy in post-ACS patients. The trial enrolled 18,144 patients who had been hospitalized for ACS within the preceding 10 days and had LDL-C between 50 and 100 mg/dL on no lipid therapy or between 50 and 80 mg/dL on low- to moderate-intensity statin therapy. Patients were randomized to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. The combination arm achieved a mean LDL-C of approximately 53 mg/dL versus 70 mg/dL in the placebo arm. After a median follow-up of six years, the primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke) was significantly reduced in the ezetimibe group (32.7% vs. 34.7%; HR 0.936, p=0.016). This result confirmed the "lower is better" hypothesis for LDL-C and established that the benefit of LDL-C lowering is mechanism-agnostic — reducing LDL-C through intestinal absorption blockade (ezetimibe) produces the same directional cardiovascular benefit as reducing it through synthesis inhibition (statins), consistent with the relationship between absolute LDL-C reduction and event reduction across drug classes.
Option A: Option A correctly describes the SHARP trial but accurately notes it does not provide evidence for ezetimibe added to statin specifically in post-ACS patients. SHARP established the role of ezetimibe-statin combination in CKD, not post-ACS management. This option is not the best answer to the specific question asked.
Option B: Option B is correct. IMPROVE-IT is the landmark trial demonstrating that adding ezetimibe to simvastatin post-ACS produces incremental cardiovascular endpoint reduction beyond statin monotherapy.
Option C: Option D: Option E:
Option C: Option C is incorrect. FOURIER studied evolocumab (a PCSK9 inhibitor), not ezetimibe. While both agents increase LDL receptor availability, they are distinct drugs studied in distinct trials; FOURIER does not serve as primary evidence for ezetimibe use post-ACS.
Option D: Option D is incorrect. ACCORD Lipid studied fenofibrate added to simvastatin in type 2 diabetes and found no incremental cardiovascular benefit in the overall population — but this fibrate result cannot be extrapolated to ezetimibe, which has a different mechanism and was positively studied in IMPROVE-IT.
Option E: Option E is incorrect. JUPITER studied rosuvastatin in primary prevention patients with elevated hsCRP and is not cited as evidence for ezetimibe use post-ACS. The two drugs have different mechanisms and different supporting evidence bases.
14. A 68-year-old man with type 2 diabetes, established ASCVD, and a recent renal transplant is on tacrolimus (a calcineurin inhibitor — an immunosuppressant) and has just been started on simvastatin 40 mg daily by his cardiologist for secondary prevention. Two weeks later he presents with severe proximal muscle weakness and a creatine kinase (CK) level 40 times the upper limit of normal. Which of the following pharmacokinetic interactions best explains why this combination significantly increases the risk of statin-induced myopathy and rhabdomyolysis?
A) Tacrolimus induces CYP3A4 expression, increasing simvastatin metabolism and paradoxically producing a toxic metabolite rather than lowering parent drug levels, which accumulates in skeletal muscle mitochondria and produces oxidative myotoxicity
B) Tacrolimus inhibits renal tubular secretion of simvastatin's glucuronide conjugates, causing urinary retention of these metabolites that are reabsorbed into the systemic circulation and converted back to the active hydroxyl acid form in skeletal muscle
C) Tacrolimus and simvastatin compete for the same P-glycoprotein (P-gp) efflux transporter in the intestinal wall, and when tacrolimus saturates this transporter, simvastatin bioavailability increases two-fold due to reduced first-pass intestinal efflux
D) Tacrolimus activates the pregnane X receptor (PXR), a nuclear receptor that upregulates CYP3A4 and MRP2 transporters, increasing simvastatin conversion to its toxic sulfoxide metabolite while simultaneously reducing biliary excretion
E) Tacrolimus is a potent inhibitor of CYP3A4, the primary enzyme responsible for simvastatin metabolism; inhibition of CYP3A4 markedly increases simvastatin and active simvastatin acid plasma concentrations, producing dose-dependent skeletal muscle toxicity — and the simvastatin 80 mg dose was specifically restricted by the FDA in 2011 due to unacceptably high myopathy risk, including in the context of CYP3A4 inhibitors
ANSWER: E
Rationale:
Simvastatin is an inactive lactone prodrug that is hydrolyzed in the gut wall and liver to its active beta-hydroxy acid form. Both the prodrug and its active metabolite are substrates for CYP3A4-mediated metabolism. Tacrolimus inhibits CYP3A4 (as well as P-glycoprotein), and co-administration with simvastatin markedly increases plasma concentrations of simvastatin and its active acid form by reducing their first-pass and systemic clearance. Elevated statin plasma concentrations increase the amount of active drug delivered to skeletal muscle, where statins impair mitochondrial function — likely through depletion of the mevalonate pathway intermediate geranylgeranyl pyrophosphate, which is required for mitochondrial membrane integrity — producing myopathy and in severe cases rhabdomyolysis (massive muscle breakdown with release of myoglobin, risk of acute kidney injury, and markedly elevated CK). The FDA issued a safety communication in 2011 restricting simvastatin 80 mg dosing due to the high myopathy risk, particularly in patients receiving concurrent CYP3A4 inhibitors such as tacrolimus, cyclosporine, amiodarone, verapamil, diltiazem, and multiple other agents. In transplant patients on calcineurin inhibitors, pravastatin and fluvastatin are generally preferred over CYP3A4-metabolized statins because of their lower interaction potential.
Option A: Option B: Option C: Option D: Option E: Option E is correct. Tacrolimus inhibits CYP3A4, increases simvastatin and active simvastatin acid plasma concentrations, and substantially elevates myopathy and rhabdomyolysis risk — an interaction reinforced by the FDA's 2011 simvastatin dose restriction.
Option A: Option A is incorrect. Tacrolimus inhibits, not induces, CYP3A4. CYP3A4 induction would actually decrease simvastatin concentrations, not increase them. The described "toxic metabolite" mechanism from induction is not the established interaction.
Option B: Option B is incorrect. Simvastatin is not primarily eliminated via renal tubular secretion of glucuronide conjugates, and this described pathway of reabsorption and skeletal muscle conversion is not an established pharmacokinetic mechanism for simvastatin toxicity.
Option C: Option C is incorrect as the primary mechanism. While both tacrolimus and simvastatin are P-glycoprotein substrates and their interaction at intestinal P-gp may contribute modestly, the dominant pharmacokinetic interaction is CYP3A4 inhibition — not P-gp saturation — and the fold-increase in exposure from P-gp alone would not explain the severity of this presentation.
Option D: Option D is incorrect. Tacrolimus does not activate PXR to induce CYP3A4; that would be an inducer effect. Tacrolimus is a CYP3A4 inhibitor. The described toxic sulfoxide metabolite mechanism is not the established pathway for simvastatin myotoxicity.
15. Niacin (nicotinic acid) was once widely used as adjunctive lipid-lowering therapy because of its ability to raise HDL-C, lower triglycerides, and reduce Lp(a) lipoprotein. However, its use has declined substantially. Which of the following best explains why extended-release niacin is no longer recommended as routine adjunctive cardiovascular therapy in patients already on statin treatment?
A) Niacin was abandoned because it causes irreversible hepatic fibrosis in more than 30% of patients taking extended-release formulations, a rate of liver toxicity that was only discovered in large-scale post-marketing surveillance and led to worldwide regulatory withdrawal
B) Niacin is now recognized as a prodrug that requires hepatic conversion to an active metabolite by nicotinamide adenine dinucleotide (NAD) synthetic enzymes, and patients on statins have reduced hepatic NAD synthesis capacity, making niacin pharmacologically inactive when combined with statin therapy
C) Niacin was replaced by PCSK9 inhibitors because niacin's mechanism of action — inhibiting hormone-sensitive lipase in adipose tissue to reduce free fatty acid flux to the liver — was found to actually increase VLDL triglyceride synthesis in patients with insulin resistance, worsening cardiovascular risk in diabetic patients
D) The AIM-HIGH trial (niacin added to simvastatin in patients with established cardiovascular disease and low HDL-C) was stopped early for futility — showing no reduction in cardiovascular events despite raising HDL-C and lowering triglycerides — and the HPS2-THRIVE trial (extended-release niacin plus laropiprant added to statin therapy) showed no cardiovascular benefit and demonstrated a significant increase in serious adverse events including new-onset diabetes, myopathy, and gastrointestinal complications, collectively removing the evidence base for routine niacin use
E) Niacin's lipid benefits are entirely negated by a pharmacokinetic interaction with statins in which statin-induced upregulation of hepatic niacin methylation accelerates niacin clearance by more than 90%, rendering therapeutic plasma concentrations unachievable when the two drug classes are co-administered
ANSWER: D
Rationale:
Despite niacin's favorable effects on multiple lipid parameters — raising HDL-C by 15–35%, lowering triglycerides by 20–50%, reducing LDL-C modestly, and lowering Lp(a) — two large randomized controlled trials failed to demonstrate the expected cardiovascular benefit when niacin was added to statin therapy. The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) was stopped early after a median follow-up of three years because an interim analysis showed no difference in the primary composite cardiovascular endpoint between the extended-release niacin plus simvastatin arm and the simvastatin plus placebo arm, despite significant improvements in HDL-C and triglycerides. The HPS2-THRIVE trial (Heart Protection Study 2 — Treatment of HDL to Reduce the Incidence of Vascular Events) enrolled over 25,000 patients and added extended-release niacin plus laropiprant (a prostaglandin D2 receptor antagonist that reduces niacin-induced flushing) to statin therapy; it found no reduction in major cardiovascular events and a significant increase in serious adverse events including new-onset diabetes (a 32% relative increase), musculoskeletal adverse events, gastrointestinal complications, and infections. These results established that raising HDL-C with niacin in patients already on statin therapy does not translate into cardiovascular benefit — supporting the concept that HDL-C as a therapeutic target may not be equivalent to HDL function — and the unfavorable safety profile further reduced enthusiasm for its routine use.
Option A: Option B: Option C: Option C contains a partial mechanistic truth (niacin does inhibit hormone-sensitive lipase in adipocytes, reducing free fatty acid flux) but misstates the clinical trial outcome. Niacin was not "replaced by PCSK9 inhibitors" based on this mechanism, and the stated worsening of VLDL synthesis is not the established explanation for niacin's abandonment.
Option D: Option D is correct. The AIM-HIGH and HPS2-THRIVE trials established that niacin added to statin therapy provides no cardiovascular benefit and produces significant harm, removing the evidence base for routine use.
Option E:
Option A: Option A is incorrect. While extended-release niacin does carry a risk of hepatotoxicity that is higher than immediate-release formulations, the described rate of irreversible hepatic fibrosis in more than 30% of patients is a significant overstatement and was not the primary reason for niacin's decline. The primary reason was trial-based evidence of no cardiovascular benefit.
Option B: Option B is incorrect. Niacin is not a prodrug requiring activation by NAD synthetic enzymes. Niacin (nicotinic acid) itself is the active compound that exerts its lipid effects primarily through inhibition of the adipose tissue HCAR2 receptor (hydroxycarboxylic acid receptor 2, also known as GPR109A) and through other mechanisms. Statin co-administration does not impair niacin pharmacological activity.
Option E: Option E is incorrect. There is no established pharmacokinetic interaction in which statin-induced methylation accelerates niacin clearance. The co-administration of statins and niacin does not prevent niacin from achieving therapeutic plasma concentrations; the trials confirmed niacin was pharmacologically active (lipid parameters improved) but did not produce cardiovascular benefit.
16. A 55-year-old woman with type 2 diabetes, an LDL-C of 128 mg/dL, and fasting triglycerides of 420 mg/dL is intolerant of statins due to myalgia. Her physician considers adding colesevelam, a bile acid sequestrant, to address her LDL-C. Which of the following correctly identifies the primary contraindication or caution relevant to this patient's clinical situation?
A) Colesevelam is absolutely contraindicated in patients with type 2 diabetes because it activates TGR5 receptors in the intestinal mucosa, producing paradoxical glucagon secretion that worsens glycemic control in all diabetic patients regardless of baseline triglyceride levels
B) Bile acid sequestrants including colesevelam are contraindicated or should be used with extreme caution when fasting triglycerides are significantly elevated — typically above 300–400 mg/dL — because they increase hepatic VLDL synthesis as a compensatory response to bile acid depletion, further raising triglycerides and potentially precipitating severe hypertriglyceridemia or pancreatitis
C) Colesevelam is contraindicated in patients with type 2 diabetes because it substantially reduces the oral bioavailability of metformin by binding it irreversibly in the gut lumen, rendering metformin ineffective and producing uncontrolled hyperglycemia in all patients on this combination
D) Bile acid sequestrants are contraindicated in post-menopausal women because they bind estrogen conjugates in the enterohepatic circulation, producing acute estrogen withdrawal symptoms and increasing bone mineral density loss to a degree that outweighs any cardiovascular benefit from LDL-C reduction
E) Colesevelam is contraindicated in patients with LDL-C above 100 mg/dL because at this level of hypercholesterolemia the drug's modest LDL-C reduction of 5–10% is insufficient to reach guideline targets, and its use delays initiation of more effective therapy — a regulatory restriction built into the FDA label
ANSWER: B
Rationale:
Bile acid sequestrants — including cholestyramine, colestipol, and colesevelam — lower LDL-C by binding bile acids in the intestinal lumen, preventing their reabsorption and interrupting the enterohepatic circulation. This forces the liver to synthesize new bile acids from cholesterol, which depletes the hepatic cholesterol pool and secondarily upregulates LDL receptor expression, increasing LDL-C clearance. However, this same compensatory response also increases hepatic VLDL production, because the liver augments lipid synthesis broadly when its cholesterol pool is reduced. In patients who already have elevated baseline triglycerides, this additional VLDL-driven triglyceride load can substantially worsen hypertriglyceridemia. In patients with triglycerides above 300–400 mg/dL, bile acid sequestrants can raise triglycerides to dangerous levels — above 500 mg/dL where acute pancreatitis risk is significant — and their use is therefore contraindicated or requires extreme caution in this population. This patient with triglycerides of 420 mg/dL represents exactly this contraindicated scenario. Notably, colesevelam does have FDA approval as an adjunct for glycemic control in type 2 diabetes (by mechanisms including TGR5 and FXR modulation), meaning her diabetes alone is not a contraindication — the elevated triglycerides are the critical issue. The physician in this case should address the hypertriglyceridemia first (with fibrates or omega-3 fatty acids) before considering any approach to LDL-C reduction.
Option A: Option B: Option B is correct. Bile acid sequestrants increase hepatic VLDL synthesis as a compensatory response, contraindicated when triglycerides are significantly elevated due to the risk of further worsening and precipitating pancreatitis.
Option C: Option D: Option E:
Option A: Option A is incorrect. Colesevelam actually has a beneficial effect on glycemic control in type 2 diabetes (it is FDA-approved as an adjunct glucose-lowering agent) and is not contraindicated in diabetic patients on the basis of TGR5 receptor glucagon stimulation.
Option C: Option C is incorrect as stated. While colesevelam can reduce the absorption of some co-administered drugs (including fat-soluble vitamins and certain oral medications), the interaction with metformin is not characterized as an absolute contraindication causing complete drug binding. Drug interaction management (separating administration times) is typically adequate. The blanket statement about rendering metformin ineffective in all patients is inaccurate.
Option D: Option D is incorrect. Bile acid sequestrants do bind bile acid conjugates but do not produce clinically significant estrogen withdrawal in post-menopausal women as a recognized contraindication. Post-menopausal status is not a listed contraindication for this drug class.
Option E: Option E is incorrect. There is no FDA label restriction that contraindications colesevelam in patients with LDL-C above a threshold due to insufficient efficacy. The concern about modest LDL-C reduction is a clinical consideration but not a regulatory contraindication.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.